How much profit has La Jolla Pharmaceutical made this year?
La Jolla Pharmaceutical has made 12.25 M USD this year.
La Jolla Pharmaceutical Net Income 2024
La Jolla Pharmaceutical Net Income
12.25 M USD
Ticker
LJPC
ISIN
US5034596040
WKN
A1XB6B
In 2024, La Jolla Pharmaceutical's profit amounted to 12.25 M USD, a 104.35% increase from the 6 M USD profit recorded in the previous year.
The La Jolla Pharmaceutical Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2026e | 75.07 |
| 2025e | 30.03 |
| 2024e | 12.25 |
| 2023e | 6 |
| 2022e | 1.04 |
| 2021 | 19.66 |
| 2020 | -39.42 |
| 2019 | -116.51 |
| 2018 | -199.47 |
| 2017 | -114.8 |
| 2016 | -78.19 |
| 2015 | -41.91 |
| 2014 | -21.31 |
| 2013 | -18.74 |
| 2012 | -8.52 |
| 2011 | -11.67 |
| 2010 | -4.23 |
| 2009 | -8.63 |
| 2008 | -62.85 |
| 2007 | -53.08 |
| 2006 | -39.45 |
| 2005 | -27.36 |
| 2004 | -40.54 |
| 2003 | -38.84 |
| 2002 | -43.32 |
La Jolla Pharmaceutical Revenue, EBIT, Net Income US5034596040 · A1XB6B
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into La Jolla Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by La Jolla Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects La Jolla Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of La Jolla Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into La Jolla Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing La Jolla Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on La Jolla Pharmaceutical’s growth potential.
La Jolla Pharmaceutical Revenue, EBIT and net profit per share
| Date | La Jolla Pharmaceutical Revenue | La Jolla Pharmaceutical EBIT | La Jolla Pharmaceutical Net Income |
|---|---|---|---|
| 2026e | 93.75 M undefined | 77.6 M undefined | 75.07 M undefined |
| 2025e | 87.23 M undefined | 44.5 M undefined | 30.03 M undefined |
| 2024e | 77.41 M undefined | 18.25 M undefined | 12.25 M undefined |
| 2023e | 65.23 M undefined | 8.93 M undefined | 6 M undefined |
| 2022e | 53.84 M undefined | 2.28 M undefined | 1.04 M undefined |
| 2021 | 75.72 M undefined | 21.83 M undefined | 19.66 M undefined |
| 2020 | 33.42 M undefined | -35.84 M undefined | -39.42 M undefined |
| 2019 | 23.05 M undefined | -109.8 M undefined | -116.51 M undefined |
| 2018 | 10.06 M undefined | -194.05 M undefined | -199.47 M undefined |
| 2017 | 0 undefined | -115.43 M undefined | -114.8 M undefined |
| 2016 | 620,000 undefined | -78.37 M undefined | -78.19 M undefined |
| 2015 | 1.06 M undefined | -41.97 M undefined | -41.91 M undefined |
| 2014 | 0 undefined | -21.34 M undefined | -21.31 M undefined |
| 2013 | 0 undefined | -17.94 M undefined | -18.74 M undefined |
| 2012 | 0 undefined | -10.74 M undefined | -8.52 M undefined |
| 2011 | 0 undefined | -2.27 M undefined | -11.67 M undefined |
| 2010 | 0 undefined | -3.93 M undefined | -4.23 M undefined |
| 2009 | 8.13 M undefined | -8.64 M undefined | -8.63 M undefined |
| 2008 | 0 undefined | -60.73 M undefined | -62.85 M undefined |
| 2007 | 0 undefined | -55.69 M undefined | -53.08 M undefined |
| 2006 | 0 undefined | -42.13 M undefined | -39.45 M undefined |
| 2005 | 0 undefined | -28 M undefined | -27.36 M undefined |
| 2004 | 0 undefined | -40.74 M undefined | -40.54 M undefined |
| 2003 | 0 undefined | -39.29 M undefined | -38.84 M undefined |
| 2002 | 0 undefined | -44.64 M undefined | -43.32 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2002 | 0 USD | -44.64 M USD | -43.32 M USD |
| 2003 | 0 USD | -39.29 M USD | -38.84 M USD |
| 2004 | 0 USD | -40.74 M USD | -40.54 M USD |
| 2005 | 0 USD | -28 M USD | -27.36 M USD |
| 2006 | 0 USD | -42.13 M USD | -39.45 M USD |
| 2007 | 0 USD | -55.69 M USD | -53.08 M USD |
| 2008 | 0 USD | -60.73 M USD | -62.85 M USD |
| 2009 | 8.13 M USD | -8.64 M USD | -8.63 M USD |
| 2010 | 0 USD | -3.93 M USD | -4.23 M USD |
| 2011 | 0 USD | -2.27 M USD | -11.67 M USD |
| 2012 | 0 USD | -10.74 M USD | -8.52 M USD |
| 2013 | 0 USD | -17.94 M USD | -18.74 M USD |
| 2014 | 0 USD | -21.34 M USD | -21.31 M USD |
| 2015 | 1.06 M USD | -41.97 M USD | -41.91 M USD |
| 2016 | 620,000 USD | -78.37 M USD | -78.19 M USD |
| 2017 | 0 USD | -115.43 M USD | -114.8 M USD |
| 2018 | 10.06 M USD | -194.05 M USD | -199.47 M USD |
| 2019 | 23.05 M USD | -109.8 M USD | -116.51 M USD |
| 2020 | 33.42 M USD | -35.84 M USD | -39.42 M USD |
| 2021 | 75.72 M USD | 21.83 M USD | 19.66 M USD |
| 2022e | 53.84 M USD | 2.28 M USD | 1.04 M USD |
| 2023e | 65.23 M USD | 8.93 M USD | 6 M USD |
| 2024e | 77.41 M USD | 18.25 M USD | 12.25 M USD |
| 2025e | 87.23 M USD | 44.5 M USD | 30.03 M USD |
| 2026e | 93.75 M USD | 77.6 M USD | 75.07 M USD |
La Jolla Pharmaceutical stock margins US5034596040 · A1XB6B
The La Jolla Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of La Jolla Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for La Jolla Pharmaceutical.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the La Jolla Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the La Jolla Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the La Jolla Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the La Jolla Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the La Jolla Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the La Jolla Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the La Jolla Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
La Jolla Pharmaceutical Margin History
| La Jolla Pharmaceutical Gross margin | La Jolla Pharmaceutical Profit margin | La Jolla Pharmaceutical EBIT margin | La Jolla Pharmaceutical Profit margin |
|---|---|---|---|
| 2026e | 82.19 % | 82.78 % | 80.08 % |
| 2025e | 82.19 % | 51.01 % | 34.42 % |
| 2024e | 82.19 % | 23.57 % | 15.83 % |
| 2023e | 82.19 % | 13.69 % | 9.19 % |
| 2022e | 82.19 % | 4.23 % | 1.94 % |
| 2021 | 82.19 % | 28.83 % | 25.96 % |
| 2020 | 76.6 % | -107.24 % | -117.95 % |
| 2019 | 89.63 % | -476.36 % | -505.47 % |
| 2018 | 83.6 % | -1,928.93 % | -1,982.8 % |
| 2017 | 82.19 % | 0 % | 0 % |
| 2016 | 82.19 % | -12,640.32 % | -12,611.29 % |
| 2015 | 82.19 % | -3,959.43 % | -3,953.77 % |
| 2014 | 82.19 % | 0 % | 0 % |
| 2013 | 82.19 % | 0 % | 0 % |
| 2012 | 82.19 % | 0 % | 0 % |
| 2011 | 82.19 % | 0 % | 0 % |
| 2010 | 82.19 % | 0 % | 0 % |
| 2009 | 82.19 % | -106.27 % | -106.15 % |
| 2008 | 82.19 % | 0 % | 0 % |
| 2007 | 82.19 % | 0 % | 0 % |
| 2006 | 82.19 % | 0 % | 0 % |
| 2005 | 82.19 % | 0 % | 0 % |
| 2004 | 82.19 % | 0 % | 0 % |
| 2003 | 82.19 % | 0 % | 0 % |
| 2002 | 82.19 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2002 | 82.19 % | 0 % | 0 % |
| 2003 | 82.19 % | 0 % | 0 % |
| 2004 | 82.19 % | 0 % | 0 % |
| 2005 | 82.19 % | 0 % | 0 % |
| 2006 | 82.19 % | 0 % | 0 % |
| 2007 | 82.19 % | 0 % | 0 % |
| 2008 | 82.19 % | 0 % | 0 % |
| 2009 | 82.19 % | -106.27 % | -106.15 % |
| 2010 | 82.19 % | 0 % | 0 % |
| 2011 | 82.19 % | 0 % | 0 % |
| 2012 | 82.19 % | 0 % | 0 % |
| 2013 | 82.19 % | 0 % | 0 % |
| 2014 | 82.19 % | 0 % | 0 % |
| 2015 | 82.19 % | -3,959.43 % | -3,953.77 % |
| 2016 | 82.19 % | -12,640.32 % | -12,611.29 % |
| 2017 | 82.19 % | 0 % | 0 % |
| 2018 | 83.6 % | -1,928.93 % | -1,982.8 % |
| 2019 | 89.63 % | -476.36 % | -505.47 % |
| 2020 | 76.6 % | -107.24 % | -117.95 % |
| 2021 | 82.19 % | 28.83 % | 25.96 % |
| 2022e | 82.19 % | 4.23 % | 1.94 % |
| 2023e | 82.19 % | 13.69 % | 9.19 % |
| 2024e | 82.19 % | 23.57 % | 15.83 % |
| 2025e | 82.19 % | 51.01 % | 34.42 % |
| 2026e | 82.19 % | 82.78 % | 80.08 % |
La Jolla Pharmaceutical Aktienanalyse
What does La Jolla Pharmaceutical do?
La Jolla Pharmaceutical Co is a biopharmaceutical company specializing in the development and marketing of medicines for the treatment of rare and severe diseases. It was founded in 1989 in San Diego, California, by physician and scientist Ivor Royston. The company's business model is focused on researching, developing, and marketing drugs for patients with rare or severe diseases. The company prioritizes the needs and requirements of patients and aims to tailor each medication to maximize effectiveness. La Jolla's main focus is on researching medications for severe and rare diseases such as sepsis, acute kidney failure, and lung inflammation. These medications are intended to help patients who have limited or no treatment options. The company's portfolio includes various drugs, with antibodies being an important component for the treatment of inflammation and autoimmune diseases. Notably, Giapreza is one of the company's well-known medications approved by the FDA in December 2017, designed to treat adult patients with severe or most severe septic shock by increasing blood pressure. LJPC-401 is another significant medication developed by La Jolla Pharmaceutical Co, intended for the treatment of lupus nephritis, an autoimmune-related kidney inflammation that affects about 50% of systemic lupus erythematosus (SLE) patients. The company is also working on the development of a medication for migraine treatment, aiming to reduce the severity and frequency of migraine attacks. Overall, La Jolla Pharmaceutical Co has made significant progress in expanding its research activities and is committed to developing innovative medications to improve the lives of patients with rare and severe diseases. The company's focus on patient needs has proven to be a strategic advantage, positioning it competitively for the future. La Jolla Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding La Jolla Pharmaceutical's Profit Margins
The profit margins of La Jolla Pharmaceutical represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of La Jolla Pharmaceutical's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating La Jolla Pharmaceutical's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
La Jolla Pharmaceutical's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When La Jolla Pharmaceutical’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about La Jolla Pharmaceutical stock
How has the profit developed compared to last year?
The profit has increased by 104.35% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does La Jolla Pharmaceutical publish its earnings?
La Jolla Pharmaceutical publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of La Jolla Pharmaceutical?
The profits of La Jolla Pharmaceutical are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of La Jolla Pharmaceutical?
You can learn more about the earnings of La Jolla Pharmaceutical by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does La Jolla Pharmaceutical pay?
Over the past 12 months, La Jolla Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, La Jolla Pharmaceutical is expected to pay a dividend of 0 USD.
What is the dividend yield of La Jolla Pharmaceutical?
The current dividend yield of La Jolla Pharmaceutical is .
When does La Jolla Pharmaceutical pay dividends?
La Jolla Pharmaceutical pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of La Jolla Pharmaceutical?
La Jolla Pharmaceutical paid dividends every year for the past 0 years.
What is the dividend of La Jolla Pharmaceutical?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is La Jolla Pharmaceutical located?
La Jolla Pharmaceutical is assigned to the 'Health' sector.
Wann musste ich die Aktien von La Jolla Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of La Jolla Pharmaceutical from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did La Jolla Pharmaceutical pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of La Jolla Pharmaceutical in the year 2023?
In the year 2023, La Jolla Pharmaceutical distributed 0 USD as dividends.
In which currency does La Jolla Pharmaceutical pay out the dividend?
The dividends of La Jolla Pharmaceutical are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The La Jolla Pharmaceutical stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von La Jolla Pharmaceutical
Our stock analysis for La Jolla Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of La Jolla Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- La Jolla Pharmaceutical Revenue
- La Jolla Pharmaceutical Net Income
- La Jolla Pharmaceutical P/E
- La Jolla Pharmaceutical P/S
- La Jolla Pharmaceutical EBIT
- La Jolla Pharmaceutical Dividend
- La Jolla Pharmaceutical Stocks
- La Jolla Pharmaceutical Market capitalization
- La Jolla Pharmaceutical Debt
- La Jolla Pharmaceutical Liabilities
- La Jolla Pharmaceutical Equity
- La Jolla Pharmaceutical AAQS
- La Jolla Pharmaceutical Employees
- La Jolla Pharmaceutical ROE
- La Jolla Pharmaceutical ROA
- La Jolla Pharmaceutical ROCE
